A Phase 3 Study Comparing Daratumumab, Lenalidomide, and
Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in
Subjects with Previously Untreated Multiple Myeloma who are
Ineligible for High Dose Therapy (Protocol
54767414MMY3008/JNJ-54767414 Daratumumab)
Please contact us for more information or to learn if you are eligible to participate.
